zelminemab

Zelminemab (AMG 301) is a fully human monoclonal antibody developed for the prevention of migraine. It acts as an antagonist of the pituitary adenylate cyclase-activating polypeptide type I (PAC1) receptor. By inhibiting this receptor, which is implicated in migraine pathophysiology through neuronal signaling pathways, zelminemab was intended to reduce migraine frequency and severity. Clinical trials demonstrated that it did not provide significant benefit over placebo in reducing monthly migraine days or other efficacy measures[2][4][5]. The drug was originally developed by Amgen and later licensed to Novartis for markets outside the USA, Canada, and Japan[4].

Other names

zelminemabAMG 301AMG301AMG-301